<DOC>
	<DOCNO>NCT01994213</DOCNO>
	<brief_summary>Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 . Phase I study show toxicity manageable . The purpose study evaluate efficacy safety profile Famitinib patient advance metastatic Gastroenteropancreatic Neuroendocrine Tumor .</brief_summary>
	<brief_title>A Study Famitinib Patients With Advanced Metastatic Gastroenteropancreatic Neuroendocrine Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Unresectable advanced metastatic , histologicallyconfirmed , gastroenteropancreatic neuroendocrine tumor . Tumors must consider welldifferentiated grade G1 grade G2 accordance WHO 2010 classification . Must least one measurable disease RECIST1.1 criterion ( tumour lesion ≥10mm long diameter , malignant lymph node ≥15mm short axis , scan layer ≤ 5 mm ) . Firstline therapy secondline treatment ( secondline treatment i.e . chemotherapy cytokine therapy firstline treatment failure resistant patient ) . No previously receive targeted therapy gastroenteropancreatic neuroendocrine tumor ( everolimus , sunitinib , tyrosine kinase VEGF inhibitor treatment ) . Age 18 75 year . ECOG Performance status ≤ 1 . Ability understand willingness sign write informed consent document . Patients smallcell carcinoma , pheochromocytoma , paraganglioma Merkel cell carcinoma Past suffering cancer , cure basal cell carcinoma cervical carcinoma situ Participated clinical trial within four week Concurrent therapy somatostatin analog ( octreotide , lanreotide , etc . ) A variety factor affect oral medication ( inability swallow , gastrointestinal resection , chronic diarrhea intestinal obstruction ) Known brain metastasis , spinal cord compression , cancer , meningitis , screen CT MRI examination reveal brain leptomeningeal disease Subjects receive surgery , chemotherapy , radiation therapy , cytokine treatment cause damage restore , time interval ≤ 4 week , wind completely heal Participants inadequate organ marrow function define : hemoglobin &lt; 90g/L platelet &lt; 100×10^9/L neutrophil &lt; 1.5×10^9/L total bilirubin ≥ 1.25×ULN serum transaminase ( ALT AST ) ≥ 1.5×ULN ( If liver metastasis present , serum transaminase≥ 2.5×ULN ) creatinine clearance rate ≤ 60ml/min cholesterol ≥ 1.5×ULN triglyceride≥ 2.5 x ULN , LVEF : &lt; 50 % Color Doppler Ultrasonography Patients uncontrollable hypertension use single agent therapy ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) . Patients Class I , myocardial ischemia myocardial infarction , arrhythmia ( include QT interval ≥ 450ms male 470ms female ) class I heart failure . Urine protein ≥ + + confirm 24hour urinary protein &gt; 1.0 g Longterm untreated wound fracture Coagulopathy bleeding tendency ( active peptic ulcer ) Previous artery / venous thromboembolic event , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism Application anticoagulants vitamin K antagonists warfarin , heparin analogue ; If prothrombin time international normalize ratio ( INR ) ≤ 1.5 , purpose prevention , use small dos warfarin ( 1mg orally , daily ) lowdose aspirin ( less 100mg daily ) allow Female : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Child bear potential , negative urine serum pregnancy test result initiate Famitinib . Male : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Preexisting thyroid dysfunction , even use medical therapy , thyroid function maintain normal range Abuse psychiatric drug dysphrenia Immunodeficiency : HIV positive , acquire immunodeficiency , congenital immunodeficiency , organ transplantation Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Famitinib</keyword>
	<keyword>Gastroenteropancreatic Neuroendocrine Tumor</keyword>
	<keyword>GEPNET</keyword>
</DOC>